Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor

Stock Track

04/15

Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.

The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.

This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1194083813"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194083813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194083813?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194083813","market":"sg","top_or_hot":-1,"title":"Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor","media":"Stock Track","content":"<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-04-15 09:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"勁方醫藥-B","start_time":0,"source_url":"","article_id":"1194083813","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194083813","pubTimestamp":1776217187,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|Genfleet Therapeutics-B盘中大涨5.48%KRAS G12D抑制剂获突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}